How has Dogwood Therapeutics's debt issuance cost amortization changed year-over-year?

Dogwood Therapeutics's debt issuance cost amortization increased by 258.5% year-over-year, from $14.61K to $52.37K.

What does debt issuance cost amortization mean?

Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).

Collegium Pharmaceutical, Inc.COLL

$819K-40.1%

Operating income-$5.1M-14.6%

Net income-$5.0M+54.4%

EPS (diluted)-$0.15+98.2%

Cash & equivalents$13.2M-24.6%

Total debt$144.9K-24.2%

Total equity$80.6M+1,038%

Total assets$95.2M-1.8%

Operating cash flow-$4.6M+2.0%

Market cap$54.14M-57.6%

Enterprise value$41.06M-64.7%

Return on equity-64.6%-29.8pp

Debt / equity0×0.0×

Current ratio5.9×-1.6×

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Dogwood Therapeutics's debt issuance cost amortization?: Dogwood Therapeutics (DWTX) reported debt issuance cost amortization of $52.37K in Q1 2025.
How has Dogwood Therapeutics's debt issuance cost amortization changed year-over-year?: Dogwood Therapeutics's debt issuance cost amortization increased by 258.5% year-over-year, from $14.61K to $52.37K.
What does debt issuance cost amortization mean?: Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).